{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:14:07Z","timestamp":1769552047353,"version":"3.49.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,20]]},"DOI":"10.4103\/0366-6999.243568","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T12:54:36Z","timestamp":1539780876000},"page":"2433-2438","source":"Crossref","is-referenced-by-count":13,"title":["Antimyoclonic Effect of Levetiracetam and Clonazepam Combined Treatment on Myoclonic Epilepsy with Ragged-Red Fiber Syndrome with m.8344A>G Mutation"],"prefix":"10.1097","volume":"131","author":[{"given":"Li-Jun","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Jun","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huai-Kuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Xin","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Wu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210129","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1590\/0004-282X20140124","article-title":"When should MERRF (myoclonus epilepsy associated with ragged-red fibers) be the diagnosis?","volume":"72","author":"Lorenzoni","year":"2014","journal-title":"Arq Neuropsiquiatr"},{"key":"R2-6-20210129","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.seizure.2017.06.010","article-title":"Management of epilepsy in MERRF syndrome","volume":"50","author":"Finsterer","year":"2017","journal-title":"Seizure"},{"key":"R3-6-20210129","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/mds.25839","article-title":"Myoclonus in mitochondrial disorders","volume":"29","author":"Mancuso","year":"2014","journal-title":"Mov Disord"},{"key":"R4-6-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/17425255.2012.644535","article-title":"Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders","volume":"8","author":"Finsterer","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R5-6-20210129","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/0006-2952(92)90590-F","article-title":"Cytochrome aa3 depletion is the cause of the deficient mitochondrial respiration induced by chronic valproate administration","volume":"43","author":"Ponchaut","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"R6-6-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1684\/epd.2016.0861","article-title":"Myoclonus and seizures in progressive myoclonus epilepsies: Pharmacology and therapeutic trials","volume":"18","author":"Michelucci","year":"2016","journal-title":"Epileptic Disord"},{"key":"R7-6-20210129","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s13311-013-0216-3","article-title":"Treatment of myoclonus","volume":"11","author":"Caviness","year":"2014","journal-title":"Neurotherapeutics"},{"key":"R8-6-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/NDT.S2937","article-title":"Levetiracetam in the treatment of epilepsy","volume":"4","author":"Abou-Khalil","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R9-6-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11940-016-0404-7","article-title":"Myoclonus: Pathophysiology and treatment options","volume":"18","author":"Levy","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"R10-6-20210129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s13311-012-0103-3","article-title":"Recovery of MERRF fibroblasts and cybrids pathophysiology by coenzyme Q10","volume":"9","author":"De la Mata","year":"2012","journal-title":"Neurotherapeutics"},{"key":"R11-6-20210129","first-page":"45","article-title":"Psoriasis, bulbar involvement, and diarrhea in late myoclonic epilepsy with ragged-red fibers-syndrome due to the m.8344 A>G tRNA (Lys) mutation","volume":"16","author":"Finsterer","year":"2017","journal-title":"Iran J Neurol"},{"key":"R12-6-20210129","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1196\/annals.1293.023","article-title":"Mitochondrial encephalomyopathies: Therapeutic approach","volume":"1011","author":"Dimauro","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"R13-6-20210129","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.bmcl.2005.03.032","article-title":"Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies","volume":"15","author":"De Simone","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"R14-6-20210129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2310\/6650.2002.31297","article-title":"Pathogenic mechanism, prophylaxis, and therapy of symptomatic acidosis induced by acetazolamide","volume":"50","author":"Filippi","year":"2002","journal-title":"J Investig Med"},{"key":"R15-6-20210129","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.0013-9580.2004.13504.x","article-title":"The mechanism of neuroprotection by topiramate in an animal model of epilepsy","volume":"45","author":"Kudin","year":"2004","journal-title":"Epilepsia"},{"key":"R16-6-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40263-013-0129-z","article-title":"The pharmacology of imepitoin: The first partial benzodiazepine receptor agonist developed for the treatment of epilepsy","volume":"28","author":"Rundfeldt","year":"2014","journal-title":"CNS Drugs"},{"key":"R17-6-20210129","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1177\/0748233713491814","article-title":"Effects of tramadol, clonazepam, and their combination on brain mitochondrial complexes","volume":"31","author":"Mohamed","year":"2015","journal-title":"Toxicol Ind Health"},{"key":"R18-6-20210129","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-6-20210129","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/j.1552-4604.2000.tb05984.x","article-title":"Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique","volume":"40","author":"Browne","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"R20-6-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-1211(01)00253-4","article-title":"Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"46","author":"Levy","year":"2001","journal-title":"Epilepsy Res"},{"key":"R21-6-20210129","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1684\/epd.2016.0846","article-title":"Myoclonus epilepsy in mitochondrial disorders","volume":"18","author":"Lamperti","year":"2016","journal-title":"Epileptic Disord"},{"key":"R22-6-20210129","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.4103\/0366-6999.168968","article-title":"Long-term effectiveness of antiepileptic drug monotherapy in partial epileptic patients: A 7-year study in an epilepsy center in china","volume":"128","author":"Zhu","year":"2015","journal-title":"Chin Med J"},{"key":"R23-6-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.parkreldis.2004.07.010","article-title":"Limited efficacy of levetiracetam on myoclonus of different etiologies","volume":"11","author":"Lim","year":"2005","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/0366-6999.243568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T19:49:32Z","timestamp":1623959372000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201810200-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,20]]},"references-count":23,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4103\/0366-6999.243568","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,20]]}}}